New Therapy for Wet Age Related Macular Degeneration

What we are studying

The objectives of this study are to evaluate the safety and efficacy of a new drug when administered in combination with Lucentis® compared to Lucentis® alone in people with wet age-related macular degeneration (AMD). In the "wet" form of AMD, abnormal blood vessels grow in the back of the eye. Sometimes these vessels leak blood or fluid that causes blurred or distorted vision. This process is also known as choroidal neovascularization (CNV).

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 50+

Eligibility Criteria

  • MUST NOT have any prior treatment for AMD in the study eye (except oral supplements of vitamins and minerals)
  • MUST NOT be diabetic
  • Provide written informed consent
  • Ability to comply with study and follow-up procedures and return for all trial visits
  • No treatment with an investigational agent in the 60 days prior for any condition.

What is involved

  • Study involvement lasts two years with monthly visits


$75 per completed visit

Contact Information

Study Coordinator
Cara Everhart

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.